Acute myeloid leukemia (AML) is a fatal disease with up to 95% of patients remaining incurable. While supportive care has been increased in quantity and quality; substantial progress of AML therapy itself is still lacking. Primarily two predicaments challenge current therapy: first, the heterogeneity of the disease; second, the phenomenon of treatment resistance. Although many AML patients initially respond to therapy, the majority of patients relapse caused by chemoresistant clones, ultimately leading to the incurability of the disease [1] [2] [3] .
Approximately a quarter of AML patients present with FLT3-gain-of-function mutations. This usually entails a constitutive activation of FLT3 receptor downstream signaling pathways and changes gene expression patterns from healthy to malignant 4 . On account of the poor prognosis of FLT3-ITD + AML patients, FLT3-inhibitors are under development and in clinical testing. Nevertheless, acquired treatment resistance persists. This underlines the necessity of a greater knowledge on the origins of resistance as well as new approaches abrogating treatment resistance 5 .
Therefore, we propose to deviate from the common strategy of target inhibition and focus on the reinforcement of negatively regulated downstream targets of wellknown oncogenes such as FLT3-ITD.
Because microRNA (miR) expression was shown to be altered by FLT3-ITD, this group of small non-coding RNAs is of interest in this work. By binding to the 3'UTRs of mRs, miRs post-transcriptionally regulate gene expression. Thus, miRs hold key regulatory functions in processes such as hematopoiesis and leukemogenesis [6] [7] [8] . In accordance with this, various miRs have been shown to impact treatment resistance as well as sensitivity toward AML therapy 9 . First clinical trials disclosed the potential of miR-inhibitors to be a promising therapeutic option 10 . Nevertheless, no miR-based experimental drugs are currently available in AML.
Therefore, we screened for differentially expressed miRs in bone marrow mononuclear cells from healthy donors and AML patients with either FLT3-wildtype, mutations in the FLT3-tyrosine kinase domain (TKD) or FLT3-ITD mutations ( Fig. 1a , Supplementary Table 1 ). Here, we found miR-451a to be significantly (p = 0.002) lower expressed in FLT3-ITD + AML patients compared to healthy individuals; while among the remaining AML samples screened, miR-451a levels were lowest in FLT3-ITD patient samples ( Fig. 1b ). In agreement with this, we observed increasing miR-451a levels upon differentiation of human and murine hematopoietic cells ( Supplementary  Figure 1a -c). In addition, we analyzed the AML patient cohort of "The Cancer Genome Atlas" (TCGA) 11 and discovered a similar miR-451a expression distribution ( Fig. 1c ). In order to confirm our observations in vitro, we assessed miR-451a levels by qPCR in FLT3-ITDtransduced U937 and 32D cells ( Fig. 1d,e ). Indeed, a stable overexpression of FLT3-ITD led to a decrease in miR-451a levels.
In contrast, interruption of FLT3-ITD signaling by treatment of MV4;11 cells with FLT3 inhibitors quizartinib and gilteritinib (currently evaluated in clinical trials) caused an increase in miR-451a expression ( Fig. 1f ). As a healthy control, we treated mononuclear cells from umbilical cord blood (UCB) with quizartinib as well as gilteritinib and observed neither a significant change in (Fig. 1g, Supplementary Figure  2a ). In addition, we demonstrated that only cells carrying FLT3-ITD were targeted by the indicated inhibitors ( Supplementary Figure 1b -d, f).
Since miR-451a correlates with an increased cancer persistence as well as recurrence 12 , we focused on the possible underlying interaction axis.
In various cancer types it was shown that mRNA of multi drug resistance protein 1 (MDR1), an ATP dependent efflux pump mediating chemoresistance, is targeted by miR-451a 12 . Presently, nothing is known about the FLT3-ITD-miR-451a-MDR1 axis in AML. Hence, we conjectured that FLT3-ITD-induced repression of miR-451a and subsequent increase in MDR1 protein is in part responsible for the poor therapy response of FLT3-ITD + AML patients. To prove this, we measured MDR1 protein amount after exogenous FLT3-ITD introduction and observed elevated MDR1 levels in FLT3-ITD transduced U937 cells by flow cytometry (Fig. 2a ) and western blot (Fig. 2b ). Upon treatment with quizartinib and gilteritinib, both miR-451a increment and decrease in MDR1 protein levels were detected (Fig. 2c) .
To corroborate our hypothesis, we determined miR-451a levels in various cell lines and measured corresponding MDR1 expression. Here, expression of MDR1 correlated inversely with miR-451a levels in the leukemic cell lines K562, MV4;11, and U937 (Supplementary Figure   Fig Figure 3c ). Furthermore, luciferase assay with the 3'UTR of MDR1 and mutated MDR1 3'UTR in MV4;11 cells verified that MDR1 is a direct target of miR-451a in the AML background ( Supplementary Figure 3d) .
To investigate whether miR-451a alone is sufficient to increase chemosensitivity, we transiently transfected MV4;11 cells with miR-451a followed by a treatment with cytarabine for 48 h. Via MTS assay, we detected a significant reduction of cell viability (Fig. 2d ). By means of Annexin V staining and flow cytometry, we determined a significant additive effect on the percentage of apoptotic cells upon cytarabine as well as gilteritinib treatment in combination with exogenous miR-451a expression ( Fig.  2e) .
In pursuance of the miR-451a-induced abrogation of chemoresistance, we included the treatment-resistant subclone MV4;11-R into our research. MV4;11-R was previously established by Stölzel et al. by continuous midostaurin treatment of parental MV4;11 cells 13 . MV4;11-R cells were shown to lack histone methyltransferase EZH2 correlating with decreased sensitivity toward multiple drugs including cytarabine and quizartinib 14 . In addition, we found an increased resistance toward gilteritinib in these cells ( Supplementary Figure  2e ). Upon treatment with either quizartinib, gilteritinib or In comparison to the GFP control, transduced FLT3-ITD led to increased MDR1 levels in U937 cells (two-tailed t-test ***p < 0.001). b Western blot analysis revealed increased MDR1 protein levels in FLT3-ITD transduced U937 cells in comparison to GFP control (c) MV4;11 cells treated for 48 h with quizartinib and gilteritinib. Flow cytometric analysis exhibited decreased MDR1 protein levels (two-tailed t-test *p < 0.05; **p < 0.01). d Transient transfection of miR-451a resulted in enhanced sensitivity of MV4;11 cells toward cytarabine. Cell viability was measured by MTS-assay (two-tailed t-test *p < 0.05). e Annexin V levels of stable miR-451a-transduced MV4;11 parental cells after 48 h treatment. Flow cytometry revealed a significant increment of Annexin V + cells in miR-451a transduced cells compared to the non-silencing control (NSC) (two-tailed t-test *p < 0.05). f MiR-451a abrogates treatment resistance of MV4;11-R cells. Resistant MV4;11 cells were stably transduced with miR-451a and treated for 48 h with quizartinib or gilteritinib. NSC non-silencing control (two-tailed t-test *p < 0.05; **p < 0.01). g MV4;11-R cells transduced with miR-451a showed decreased MDR1 levels compared to the NSC. All experiments were performed at least three times (two-tailed t-test *p < 0.05). h Western blot analysis revealed reduced MDR1 protein levels in miR-451a transduced MV4;11-R cells in comparison to NSC control. i Proposed scheme of the FLT3-ITD-MDR1-miR-451a axis cytarabine, cell growth was inhibited in MV4;11 parental cells, whereas MV4;11-R cells only showed decelerated growth ( Supplementary Figure 2f-h) . Consequently, we stably transduced MV4;11-R cells with miR-451a and observed a restored drug sensitivity toward FLT3 inhibitors quizartinib and gilteritinib (Fig. 2f) . Moreover, exogenous miR-451a resulted in decreased MDR1 protein levels as measured by flow cytometry (Fig. 2g ) and western blot (Fig. 2h) .
As proof of principle, we were interested whether MDR1 inhibitor tariquidar was able to mimick miR-451amediated effects on chemoresistance toward quizartinib. Therefore, we treated MV4;11 as well as MV4;11-R cells with tariquidar in combination with quizartinib and analyzed cell viability. Here, tariquidar enhanced quizartinib-mediated effects and partially abrogated chemoresistance of MV4;11-R cells (Supplementary Figure  3e) .
Overall, our data give insights into one molecular cause of the poor prognosis conferred by FLT3-ITD. We demonstrated that MDR1 expression is indirectly targeted by FLT3-ITD through miR-451a ( Fig. 2i ). Current treatment drafts of FLT3-ITD + AML patients trend toward inhibition of FLT3-ITD function; since these encounter resistance impediments similar to the standard treatment regimen, sole inhibition appears to be insufficient. Hence, we propose to not only focus on inhibition of FLT3-ITD function but on mimicking the effects of its negatively regulated downstream targets. MiR-451a is such a negatively regulated target and was able to increase chemosensitivity by targeting MDR1 in vitro. To date, therapeutics inhibiting MDR1 failed application in medical practice, especially, due to toxicity-associated with pharmacokinetic drug interactions 15 . Here, miR-451a as active substance may circumvent this plight and render treatment more effective. Succeeding research ought to determine how administration of miR-451a may be feasible for future therapy.
